摘要
目的:确定卵巢癌患者血清血管内皮生长因子(VEGF)水平,探讨其临床价值。方法:采用酶联免疫吸附法(ELISA),对10例健康妇女(对照组),14例卵巢良性肿瘤(良性组)及42例卵巢恶性肿瘤(恶性组)进行血清VEGF含量分析。结果:①恶性组术前血清VEGF含量显著高于良性组及对照组(P<0.01)。⑦恶性组血清VEGF含量与卵巢癌临床分期、淋巴结、大网膜转移关系密切(P<0.05)。结论:检测血清VEGF含量异常升高,并与卵巢癌的临床分期,淋巴结转移关系密切。通过检测血清VEGF水平能在一定程度上反映卵巢癌患者的疗效及预后。
Objective: To study the clinical significance of the serum VEGF level in the patients with ovarian carcinomas. Methods: The serum VEGF level in the patients with ovarian neoplasm (42 cases of ovarian carcinomas, 14 of benign tumors) and 10 healthy women as controls was determined by enzyme linked immunosorbent assay(ELISA). Results: ①The preoperative serum VEGF in malignant groups was significant difference compared with normal control or the patients with benign tumor (P < 0.01 ). ② There was significant relationship between the preoperative serum VEGF level and TNM stage and lymph node metastasis ( P < 0. 05 respectively). Conclusions: The serum VEGF level is higher in malignant tumors, and the level may be used as a prognostic marker for monitoring the status of advanced ovarian cancer.
出处
《黑龙江医药科学》
2005年第1期24-25,共2页
Heilongjiang Medicine and Pharmacy
关键词
血管内皮生长因子
卵巢癌
血清
rascular endothelial growth factor
ovarian carcinoma
serum
